ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 196

The Pyrin Domain-Only Protein POP1 Inhibits NLRP3-Dependent Inflammatory Disease

Lucia Almeida1, Sonal Khare2, Alexander Misharin3, Rajul Patel2, Rojo Ratsinmandresy2, Melissa Wallin2, Harris R. Perlman4, David Greaves5, Hal M. Hoffman6, Andrea Dorfleutner1 and Christian Stehlik2, 1Medicine/Rheumatology, Northwestern University, Feinberg School of Medicine, Chicago, IL, 2Northwestern University, Chicago, IL, 3Medicine/Rheumatology, Northwestern University, Chicago, IL, 4Feinberg School of Medicine, Northwestern University, Chicago, IL, 5University of Oxford, oxford, England, 6University of California at San Diego, San Diego, CA

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: IL-1/IL-18 and inflammasome activation

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Innate Immunity and Rheumatic Disease Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: In response to infections and tissue damage NLRP3 and ASC-containing inflammasome protein complexes are assembled, which promote caspase-1 activation, IL-1b and IL-18 processing and release and pyroptosis. Caspase-1 is also responsible for the release of ASC danger particles, which perpetuate and propagate inflammasome responses to bystander cells. However, excessive or persistent activation causes inflammatory diseases, including Cryopyrin Associated Periodic Syndrome (CAPS). Hence, a well-balanced inflammasome response is crucial to maintain homeostasis. Therefore inflammasome regulatory proteins likely exist to maintain an appropriate level of activity and in particular, to limit its activity during the resolution phase of this response. We propose that PYD-only protein POP1 is one of these proteins.

Methods: Available datasets of CAPS patients in the NCBI Gene Expression Omnibus database were analysed for POP1 expression.   Monocyte/macrophage-expressing POP1 transgenic (TG) mice were generated and crossed with conditional NLRP3A350V and Lysozyme M-Cre recombinase (CreL)-expressing mice. Offspring were analysed for CAPS by measuring body weight, survival and histological analysis. ASC-GFP particles were sorted by flow cytometry and used to trigger secondary inflammasome responses, which were analyzed in vitro and in vivo. Cytokines were analyzed by ELISA.

Results: Here we show that the PYD-only protein POP1 inhibits ASC-dependent inflammasome assembly by preventing inflammasome nucleation, and consequently interferes with caspase-1 activation, IL-1b and IL-18 release, pyroptosis and the release of ASC danger particles. Mice lack POP1, but transgenic POP1 expression in monocytes and macrophages protects mice from systemic inflammation triggered by ASC danger particles and CAPS-linked NLRP3mutations. CAPS patients exhibit reduced POP1 expression, suggesting that impaired POP1 expression may contribute to excessive inflammasome-driven inflammation. We further show that POP1 expression itself is regulated by IL-1b and propose that POP1 provides a regulatory feedback loop that shuts down excessive inflammatory responses and thereby prevents systemic inflammation.

Conclusion: POP1 provides a unique mechanism evolved in humans to enable more control for the essential inflammasome-mediated host defense system, thereby guarding against excessive and out of control responses that can cause inflammatory disease.


Disclosure: L. Almeida, None; S. Khare, None; A. Misharin, None; R. Patel, None; R. Ratsinmandresy, None; M. Wallin, None; H. R. Perlman, None; D. Greaves, None; H. M. Hoffman, Novartis Pharmaceutical Corporation, 8,Novartis and Sobi, 5; A. Dorfleutner, None; C. Stehlik, None.

To cite this abstract in AMA style:

Almeida L, Khare S, Misharin A, Patel R, Ratsinmandresy R, Wallin M, Perlman HR, Greaves D, Hoffman HM, Dorfleutner A, Stehlik C. The Pyrin Domain-Only Protein POP1 Inhibits NLRP3-Dependent Inflammatory Disease [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/the-pyrin-domain-only-protein-pop1-inhibits-nlrp3-dependent-inflammatory-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-pyrin-domain-only-protein-pop1-inhibits-nlrp3-dependent-inflammatory-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology